Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes

Technology appraisal guidance
Reference number: TA583
Published: 05 June 2019

History

Declaration of interests

Register of interests (PDF 152 KB)

Published:

17 February 2020

Expected publication

Equality Impact Assessment (Guidance development) (PDF 145 KB)

Published:

05 June 2019

Final draft guidance

Final draft guidance
Final appraisal document (PDF 241 KB)

Published:

26 April 2019
Committee papers (PDF 8.94 MB)

Published:

26 April 2019
Public committee slides ACM1 - clinical effectiveness (PDF 888 KB)

Published:

26 April 2019
Public committee slides ACM1 - cost effectiveness (PDF 335 KB)

Published:

26 April 2019
Public committee slides ACM2 (PDF 546 KB)

Published:

26 April 2019

Invitation to participate

Final scope (PDF 252 KB)

Published:

01 August 2018
Final matrix (PDF 264 KB)

Published:

01 August 2018
NICE's response to comments on the draft scope and provisional matrix (PDF 286 KB)

Published:

01 August 2018